DGAP-News: Sangui Biotech International Inc.

DGAP-News: Sangui Biotech International Inc.: New expert consensus underlines the outstanding effect of Granulox in chronic wounds

DGAP-News: Sangui BioTech International Inc. / Key word(s): Miscellaneous Sangui BioTech International Inc.: New expert consensus underlines the outstanding effect of Granulox in chronic wounds

25.11.2016 / 11:19 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Sangui BioTech: - New expert consensus underlines the outstanding effect of Granulox in chronic wounds

Witten, November, 25/11/2016:

In the edition 5/2016 of the learned journal "Wundmanagement" (Wundmanagement 2016; 5: 276-284), the official notification body of the initiative "Chronische Wunden e.V" (ICW eV), the "Expert consensus to practical aspects of wound therapy with hemoglobin spray" has been published. This publication is another proof that the wound spray Granulox contributes to a faster wound healing.

The recommendation was reconciled by well-known experts from the DACH region. Which includes Prof. Dr. med. Joachim Dissemond, board member of ICW e.V. and head of ICW-certified dermatological wound care at the university hospital in Essen (Germany), Veronika Gerber, first chairman of ICW e.V., Prof. Dr. Knut Kröger, deputy chairman of ICW e.V. as well as Kerstin Protz, specialist author and consultant for wound care concepts.

Austria is represented by Prim. Univ. Prof. Dr. med. Robert Strohal and the wound care manager Peter Kurz. PD Dr. med. Severin Läuchli, acting president of the European Wound Management Association (EWMA) and head of dermatology at the University of Zurich and Siegfried Uttenweiler are responsible for the Swiss vote.

The outstanding contribution not only considers the well-known methods and possible product combinations of Granulox. It also focuses on the presentation of the novel M.O.I.S.T concept for the local treatment of chronic wounds. For the first time, oxygen as well as further substances or methods with a supporting effect, such as growth factors, are included in the existing concept for the local therapy of chronic wounds. This is a milestone for the relevance of oxygen in the area of ??wound healing. The expert consensus also shows a clear and precise application algorithm for Granulox. Accordingly, Granulox should be used every three days for both acute and chronic wounds which have not decreased by at least 40% after four weeks of conventional treatment and thus meet the criterion of slowed wound healing. Healing progress should be reevaluated at 4-week intervals or in case of complications.

The expert consensus clarifies that Granulox is well suited to provide wounds with additional oxygen. In addition, the healing processes of hypoxic wounds can be supported, especially if a sufficient improvement in wound healing by standard therapies could not be achieved. Thus the publication once again shows that Granulox should be integrated as a treatment method in the care of chronic wounds.

"We are delighted that such a high-caliber international expert group emphasizes the role of Granulox in modern wound treatment and calls for a systematic use in non-healing wounds," commented Michael Sander, Managing Director of Sastomed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox.

The complete article is available as downloadable at: http://granulox.de/ downloads/Wundmanagement_5_2016_Konsensus_DE.pdf

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact: Sangui Biotech International, Inc. Thomas Striepe Fax: +49 (2302) 915191 e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward- looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

---------------------------------------------------------------------------

25.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

---------------------------------------------------------------------------

524269 25.11.2016